Research programme: anti-thrombopoietin receptor monoclonal antibodies - Alexion

Drug Profile

Research programme: anti-thrombopoietin receptor monoclonal antibodies - Alexion

Alternative Names: Anti-c-Mpl receptor monoclonal antibodies; Anti-cMPL receptor monoclonal antibodies; Anti-cMPLr monoclonal antibodies; Anti-TPO receptor monoclonal antibodies; cMPL receptor agonist antibodies; Thrombopoietin receptor agonist antibodies; TPO receptor agonist antibodies

Latest Information Update: 02 May 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombocytopenia

Most Recent Events

  • 02 May 2005 Discontinued - Preclinical for Thrombocytopenia in USA (unspecified route)
  • 08 Jan 2004 Alexion and XOMA have entered into an agreement to co-develop a c-MPL agonist antibody in thrombocytopenia
  • 30 May 2001 Preclinical trials in Thrombocytopenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top